Repeated immune and non immune insults to the graft after heart transplantation

Immunology Letters

Volumn 141, Issue 1, 2011, Pages 18-27

  Crudele, Valeria ^a   Picascia, Antonietta ^a   Infante, Teresa ^b   Grimaldi, Vincenzo ^a   Maiello, Ciro ^c   Napoli, Claudio ^a,b  

^a SECOND UNIVERSITY OF NAPLES   (Italy)

^b IRCCS SDN   (Italy)

^c MONALDI HOSPITAL   (Italy)

Author keywords

Acute and chronic rejection; Cardiac Allograft Vasculopathy (CAV); Heart transplantation; Immunosuppressive therapy

Indexed keywords

ANTINEOPLASTIC AGENT; AUTOANTIGEN; AZATHIOPRINE; CALCINEURIN INHIBITOR; CD4 ANTIGEN; CD8 ANTIGEN; CEFPIROME; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DENILEUKIN DIFTITOX; DOXORUBICIN; EMD 525797; EVEROLIMUS; GLUCOCORTICOID; HLA ANTIBODY; HLA ANTIGEN CLASS 1; HLA ANTIGEN CLASS 2; IMMUNOSUPPRESSIVE AGENT; MOXIFLOXACIN; PIOGLITAZONE; PREDNISONE; PREGABALIN; RITUXIMAB; ROBATUMUMAB; ROSIGLITAZONE; SITAXSENTAN; TESTOSTERONE; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINCRISTINE SULFATE;

ABSCESS; ACUTE GRAFT REJECTION; ANTIBODY RESPONSE; ANTIBODY SPECIFICITY; ANTIGEN PRESENTING CELL; AUTOIMMUNITY; B CELL LYMPHOMA; CARDIAC ALLOGRAFT VASCULOPATHY; CARDIAC GRAFT REJECTION; CHRONIC GRAFT REJECTION; CYTOMEGALOVIRUS INFECTION; DIASTOLIC HEART FAILURE; DISEASE COURSE; DISEASE PREDISPOSITION; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; GLUCOSE INTOLERANCE; GRAFT SURVIVAL; HEART TRANSPLANTATION; HISTOCOMPATIBILITY; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; HYPOGONADISM; IMMUNE RESPONSE; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; INFECTION SENSITIVITY; MAINTENANCE THERAPY; MALIGNANT NEOPLASTIC DISEASE; NEPHROTOXICITY; NEUROTOXICITY; PERIPHERAL T CELL LYMPHOMA; PRIORITY JOURNAL; REVIEW; RISK FACTOR; SIDE EFFECT; SINGLE DRUG DOSE; SKIN CANCER; SOLID TUMOR; SURVIVAL TIME; TREATMENT OUTCOME;

ACUTE DISEASE; AGE FACTORS; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; CYTOMEGALOVIRUS INFECTIONS; DIABETES COMPLICATIONS; DONOR SELECTION; ENDOTHELIAL CELLS; FEMALE; GRAFT REJECTION; HEART TRANSPLANTATION; HISTOCOMPATIBILITY; HLA ANTIGENS; HUMANS; HYPERTENSION; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; ISCHEMIA; MALE; NEOPLASMS; TISSUE AND ORGAN HARVESTING; TRANSPLANTATION TOLERANCE;

EID: 80955142871     PISSN: 01652478     EISSN: 18790542     Source Type: Journal    
DOI: 10.1016/j.imlet.2011.07.004     Document Type: Review

References (90)

1. Nankivell B.J., Alexander S.I. Rejection of the kidney allograft. N Engl J Med 2010, 363:1451-1462.
2. Moll S., Pascual M. Humoral rejection of organ allografts. Am J Transplant 2005, 5:2611-2618.
3. Terasaki P.I. Humoral theory of transplantation. Am J Transplant 2003, 3:665-673.
4. Eckman P.M. Immunosuppression in the sensitized heart transplant recipient. Curr Opin Organ Transplant 2010, 15:650-656.
5. Hornick P., Rose M. Chronic rejection in the heart. Methods Mol Biol 2006, 333:131-144.
6. Christie J.D., Edwards L.B., Kucheryavaya A.Y., Aurora P., Dobbels F., Kirk R., et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult lung and heart-lung transplant report 2010. J Heart Lung Transplant 2010, 29:1104-1118.
7. Stehlik J., Edwards L.B., Kucheryavaya A.Y., Aurora P., Christie J.D., Kirk R., et al. The Registry of the International Society for Heart and Lung Transplantation: twenty-seventh official adult heart transplant report - 2010. J Heart Lung Transplant 2010, 29:1089-1103.
8. Jarcho J.A. Fear of rejection - monitoring the heart-transplant recipient. N Engl J Med 2010, 362:1932-1933.
9. Afzali B., Lechler R.I., Hernandez-Fuentes M.P. Allorecognition and the alloresponse: clinical implications. Tissue Antigens 2007, 69:545-556.
10. Velez M., Johnson M.R. Management of allosensitized cardiac transplant candidates. Transplant Rev 2009, 23:235-247.
11. Sánchez-Fueyo A., Strom T.B. Immunologic basis of graft rejection and tolerance following transplantation of liver or other solid organs. Gastroenterology 2011, 140:51-64.
12. Webber S.A., McCurry K., Zeevi A. Heart and lung transplantation in children. Lancet 2006, 368:53-69.
13. Nath D.S., Tiriveedhi V., Basha H.I., Phelan D., Moazami N., Ewald G.A., et al. A role for antibodies to human leukocyte antigens, collagen-V, and K-α1-tubulin in antibody-mediated rejection and cardiac allograft vasculopathy. Transplantation. 2011, [Epub ahead of print].
14. Reed E.F., Demetris A.J., Hammond E., Itescu S., Kobashigawa J.A., Reinsmoen N.L., et al. Acute antibody-mediated rejection of cardiac transplants. J Heart Lung Transplant 2006, 25:153-159.
15. Kobashigawa J., Mehra M., West L., Kerman R., George J., Rose M., et al. Report from a consensus conference on the sensitized patient awaiting heart transplantation. J Heart Lung Transplant 2009, 28:213-225.
16. Rodriguez E.R., Skojec D.V., Tan C.D., Zachary A.A., Kasper E.K., Conte J.V., et al. Antibody-mediated rejection in human cardiac allografts: evaluation of immunoglobulins and complement activation products C4d and C3d as markers. Am J Transplant 2005, 5:2778-2785.
17. Crespo-Leiro M.G., Veiga-Barreiro A., Domenech N., Paniagua M.J., Piñón P., González-Cuesta M., et al. Humoral heart rejection [severe allograft dysfunction with no signs of cellular rejection or ischemia]: incidence, management, and the value of C4d for diagnosis. Am J Transplant 2005, 5:2560-2564.
18. Austin B.A., Taylor D.O. Surrogate markers of rejection. Curr Opin Organ Transplant 2010, 15:645-649.
19. Koelman C.A., Vaessen L.M., Balk A.H., Weimar W., Doxiadis I.I., Claas F.H. Donor-derived soluble HLA plasma levels cannot be used to monitor graft rejection in heart transplant recipients. Transpl Immunol 2000, 8:57-64.
20. Frick M., Antretter H., Pachinger O., Pölzl G. Biomarker for diagnosis of rejection after heart transplantation. Herz 2010, 35:11-16.
21. Schmauss D., Weis M. Cardiac allograft vasculopathy: recent developments. Circulation 2008, 117:2131-2141.
22. Millington T.M., Madsen J.C. Innate immunity and cardiac allograft rejection. Kidney Int 2010, 78:S18-S21.
23. Weiss M.J., Madsen J.C., Rosengard B.R., Allan J.S. Mechanisms of chronic rejection in cardiothoracic transplantation. Front Biosci 2010, 13:2980-2988.
24. Wehner J., Morrell C.N., Reynolds T., Rodriguez E.R., Baldwin W.M. Antibody and complement in transplant vasculopathy. Circ Res 2007, 100:191-203.
25. Kroemer A., Edtinger K., Li X.C. The innate natural Killer cells in transplant rejection and tolerance induction. Curr Opin Organ Transplant 2008, 13:339-343.
26. Vassalli G., Gallino A., Weis M., von Scheidt W., Kappenberger L., von Segesser L.K., et al. Alloimmunity and non immunologic risk factors in cardiac allograft vasculopathy. Eur Heart J 2003, 24:1180-1188.
27. Saraiva F., Matos V., Gonçalves L., Antunes M., Providência L.A. Complications of endomyocardial biopsy in heart transplant patients: a retrospective study of 2117 consecutive procedures. Transplant Proc 2011, 43:1908-1912.
28. Mehra M.R. Contemporary concepts in prevention and treatment of cardiac allograft vasculopathy. Am J Transplant 2006, 6:1248-1256.
29. Terasaki P.I., Cai J. Humoral theory of transplantation: further evidence. Curr Opin Immunol 2005, 17:541-545.
30. Saleem M., Gustafsson K., Fabre J.W. Attempts to demonstrate indirect T cell allorecognition of donor MHC peptides in transplant patients. Immunol Lett 1996, 54:21-24.
31. Uber W.E., Self S.E., Van Bakel A.B., Pereira N.L. Acute antibody-mediated rejection following heart transplantation. Am J Transplant 2007, 7:2064-2074.
32. Kobashigawa J.A. Contemporary concepts in noncellular rejection. Heart Fail Clin 2007, 3:11-15.
33. Morrell C.N., Murata K., Swaim A.M., Mason E., Martin T.V., Thompson L.E., et al. In vivo platelet-endothelial cell interactions in response to major histocompatibility complex alloantibody. Circ Res 2008, 102:777-785.
34. Zhang X., Reed E.F. Effect of antibodies on endothelium. Am J Transplant 2009, 9:2459-2465.
35. Nath D.S., Basha H.I., Mohanakumar T. Antihuman leukocyte antigen antibody-induced autoimmunity: role in chronic rejection. Curr Opin Organ Transplant 2010, 15:16-20.
36. Win T.S., Pettigrew G.J. Humoral autoimmunity and transplant vasculopathy: when allo is not enough. Transplantation 2010, 90:113-120.
37. Mahesh B., Leong H.S., McCormack A., Sarathchandra P., Holder A., Rose M.L. Autoantibodies to vimentin cause accelerated rejection of cardiac allografts. Am J Pathol 2007, 170:1415-1427.
38. + T cells directly recognize allogeneic endothelial cells in vitro and in vivo. J Immunol 2007, 179:4397-4404.
39. Choy J.C., Wang Y., Tellides G., Pober J.S. Induction of inducible NO synthase in bystander human T cells increases allogeneic responses in the vasculature. Proc Natl Acad Sci USA 2007, 104:1313-1318.
40. Al-Lamki R.S., Bradley J.R., Pober J.S. Endothelial cells in allograft rejection. Transplantation 2008, 86:1340-1348.
41. Taflin C., Charron D., Glotz D., Mooney N. Immunological function of the endothelial cell within the setting of organ transplantation. Immunol Lett 2011, [Epub ahead of print].
42. Al-Lamki R.S., Wang J., Tolkovsky A.M., Bradley J.A., Griffin J.L., Thiru S., et al. TL1A both promotes and protects from renal inflammation and injury. J Am Soc Nephrol 2008, 19:953-960.
43. Zemani F., Silvestre J.S., Fauvel-Lafeve F., Bruel A., Vilar J., Bieche I., et al. Ex vivo priming of endothelial progenitor cells with SDF-1 before transplantation could increase their proangiogenic potential. Arterioscler Thromb Vasc Biol 2008, 28:644-650.
44. Reinsmoen N.L., Nelson K., Zeevi A. Anti-HLA antibody analysis and crossmatching in heart and lung transplantation. Transpl Immunol 2004, 13:63-71.
45. Opelz G., Wujciak T. The influence of HLA compatibility on graft survival after heart transplantation. N Engl J Med 1994, 330:816-819.
46. Kaczmarek I., Deutsch M.A., Rohrer M.E., Beiras-Fernandez A., Groetzner J., Daebritz S., et al. HLA-DR matching improves survival after heart transplantation: is it time to change allocation policies?. J Heart Lung Transplant 2006, 25:1057-1062.
47. Smith J.D., Banner N.R., Hamour I.M., Ozawa M., Goh A., Robinson D., et al. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011, 11:312-319.
48. Reinsmoen N.L., Cornett K.M., Kloehn R., Burnette A.D., McHugh L., Flewellen B.K., et al. Pretransplant donor-specific and non-specific immune parameters associated with early acute rejection. Transplantation 2008, 85:462-470.
49. Ho E.K., Vlad G., Colovai A.I., Vasilescu E.R., Schwartz J., Sondermeijer H., et al. Alloantibodies in heart transplantation. Hum Immunol 2009, 70:825-829.
50. Ho E.K., Vlad G., Vasilescu E.R., de la Torre L., Colovai A.I., Burke E., et al. Pre- and post transplantation allosensitization in heart allograft recipients: major impact of de novo alloantibody production on allograft survival. Hum Immunol 2011, 72:5-10.
51. Kaczmarek I., Deutsch M.A., Saduni S., Brenner P., Schmauss D., Daebritz S.H., et al. Succesfull management of antibody mediated cardiac allograft rejection with combined immunoadsorption and anti-CD20 monoclonal antibody treatment: case report and literature review. J Heart Lung Transplant 2007, 26:511-515.
52. Li F., Atz M.E., Reed E.F. Human leukocyte antigen antibodies in chronic transplant vasculopathy-mechanisms and pathways. Curr Opin Immunol 2009, 21:557-562.
53. Zhang Q., Cecka J.M., Gjertson D.W., Ge P., Rose M.L., Patel J.K., et al. HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation 2011, 91:1153-1158.
54. Jindra P.T., Zhang X., Mulder A., Claas F., Veale J., Jin Y.P., et al. Anti-HLA antibodies can induce endothelial cell survival or proliferation depending on their concentration. Transplantation 2006, 82:S33-S35.
55. El-Sawy T., Miura M., Fairchild R. Early T cell response to allografts occurring prior to alloantigen priming up-regulates innate-mediated inflammation and graft necrosis. Am J Pathol 2004, 165:147-157.
56. Potena L., Holweg C.T., Chin C., Luikart H., Weisshaar D., Narasimhan B., et al. Acute rejection and cardiac allograft vascular disease is reduced by suppression of subclinical cytomegalovirus infection. Transplantation 2006, 82:398-405.
57. Rubin R.H. Prevention and treatment of cytomegalovirus disease in heart transplant patients. J Heart Lung Transplant 2000, 19:731-735.
58. Weis M., Kledal T.N., Lin K.Y., Panchal S.N., Gao S.Z., Valantine H.A., et al. Cytomegalovirus infection impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine in transplant arteriosclerosis. Circulation 2004, 109:500-505.
59. Squizzato A., Gerdes V.E., Büller H.R. Effects of human cytomegalovirus infection on the coagulation system. Thromb Haemost 2005, 93:403-410.
60. Fishman J.A., Emery V., Freeman R., Pascual M., Rostaing L., Schlitt H.J., et al. Cytomegalovirus in transplantation - challenging the status quo. Clin Transplant 2007, 21:149-158.
61. Zweers N., Petersen A.H., van der Hoeven J.A., de Haan A., Ploeg R.J., de Leij L.F., et al. Donor brain death aggravates chronic rejection after lung transplantation in rats. Transplantation 2004, 78:1251-1258.
62. Anyanwu A.C., Banner N.R., Mitchell A.G., Khaghani A., Yacoub M.H. Low incidence and severity of transplant-associated coronary artery disease in heart transplants from live donors. J Heart Lung Transplant 2003, 22:281-286.
63. Michaels P.J., Esplejo M.L., Kobashigawa J., Alejos J.C., Burch C., Takemoto S., et al. Humoral rejection in cardiac transplantation: risk factors, hemodynamic consequences and relationship to transplant coronary artery disease. J Heart Lung Transplant 2003, 22:58-69.
64. Kellerman L., Neugut A., Burke B., Mancini D. Comparison of the incidence of de novo solid malignancies after heart transplantation to that in the general population. Am J Cardiol 2009, 103:562-566.
65. Chan M., Pearson G.J. New advances in antirejection therapy. Curr Opin Cardiol 2007, 22:117-122.
66. Senzolo M., Ferronato C., Burra P. Neurologic complications after solid organ transplantation. Transpl Int 2009, 22:269-278.
67. Dandel M., Hummel M., Wellnhofer E., Kapell S., Lehmkuhl H.B., Hetzer R. Association between acute rejection and cardiac allograft vasculopathy. J Heart Lung Transplant 2003, 22:1064-1065.
68. Dandel M., Hetzer R. Impact of immunosuppressive drugs on the development of cardiac allograft vasculopathy. Curr Vasc Pharmacol 2010, 8:706-719.
69. Dandel M., Lehmkuhl H.B., Knosalla C., Hetzer R. Impact of different long-term maintenance immunosuppressive therapy strategies on patients' outcome after heart transplantation. Transpl Immunol 2010, 23:93-103.
70. Baur B., Oroszlan M., Hess O., Carrel T., Mohacsi P. Efficacy and safety of sirolimus and everolimus in heart transplant patients: a retrospective analysis. Transplant Proc 2011, 43:1853-1861.
71. Campara M., Tzvetanov I.G., Oberholzer J. Interleukin-2 receptor blockade with humanized monoclonal antibody for solid organ transplantation. Expert Opin Biol Ther 2010, 10:959-969.
72. Bierl C., Miller B., Prak E.L., Gasiewski A., Kearns J., Tsai D., et al. Antibody-mediated rejection in heart transplant recipients: potential efficacy of B-cell depletion and antibody removal. Clin Transpl 2006, 489-496.
73. LaCorcia G., Swistak M., Lawendowski C., Duan S., Weeden T., Nahill S., et al. Polyclonal rabbit antithymocyte globulin exhibits consistent immunosuppressive capabilities beyond cell depletion. Transplantation 2009, 87:966-974.
74. Fehr T., Sykes M. Clinical experience with mixed chimerism to induce transplantation tolerance. Transpl Int 2008, 21:1118-1135.
75. Slavin S., Strober S., Fuks Z., Kaplan H.S. Long-term survival of skin allografts in mice treated with fractionated total lymphoid irradiation. Science 1976, 193:1252-1254.
76. Slavin S., Reitz B., Bieber C.P., Kaplan H.S., Strober S. Transplantation tolerance in adult rats using total lymphoid irradiation: permanent survival of skin, heart, and marrow allografts. J Exp Med 1978, 147:700-707.
77. Scandling J.D., Busque S., Dejbakhsh-Jones S., Benike C., Millan M.T., Shizuru J.A., et al. Tolerance and chimerism after renal and hematopoietic-cell transplantation. N Engl J Med 2008, 358:362-368.
78. Bonde S., Chan K.M., Zavazava N. ES-cell derived hematopoietic cells induce transplantation tolerance. PLoS ONE 2008, 3:e3212.
79. Babic A.M. Extracorporeal photopheresis: lighting the way to immunomodulation. Am J Hematol 2008, 83:589-591.
80. Barr M.L., Baker C.J., Schenkel F.A., McLaughlin S.N., Stouch B.C., Starnes V.A., et al. Prophylactic photopheresis and chronic rejection: effects on graft intimal hyperplasia in cardiac transplantation. Clin Transplant 2000, 14:162-166.
81. Marques M.B., Schwartz J. Update on extracorporeal photopheresis in heart and lung transplantation. J Clin Apher 2010, [Epub ahead of print].
82. Lamioni A., Parisi F., Isacchi G., Giorda E., Di Cesare S., Landolfo A., et al. The immunological effects of extracorporeal photopheresis unraveled: induction of tolerogenic dendritic cells in vitro and regulatory T cells in vivo. Transplantation 2005, 79:846-850.
83. Barr M.L., Meiser B.M., Eisen H.J., Roberts R.F., Livi U., Dall'Amico R., et al. Photopheresis for the prevention of rejection in cardiac transplantation. Photopheresis Transplantation Study Group. N Engl J Med 1998, 339:1744-1751.
84. Barr M.L. Photopheresis in transplantation: future research and directions. Transplant Proc 1998, 30:2248-2250.
85. Dall'Amico R., Livi U., Milano A., Montini G., Andreetta B., Murer L., et al. Extracorporeal photochemotherapy as adjuvant treatment of heart transplant recipients with recurrent rejection. Transplantation 1995, 60:45-49.
86. Dall'Amico R., Montini G., Murer L., Andreetta B., Zacchello G., Gambino A., et al. Extracorporeal photochemotherapy after cardiac transplantation: a new therapeutic approach to allograft rejection. Int J Artif Organs 2000, 23:49-54.
87. Everitt M.D., Pahl E., Schechtman K.B., Zheng J., Ringewald J.M., L'ecuyer T., et al. Rejection with hemodynamic compromise in the current era of pediatric heart transplantation: a multi-institutional study. J Heart Lung Transplant 2011, 30:282-288.
88. Ingelfinger J.R., Schwartz R.S. Immunosuppression - the promise of specificity. N Engl J Med 2005, 353:836-839.
89. Shao W., Chen J., Dai H., Peng Y., Wang F., Xia J., et al. Combination of monoclonal antibodies with DST inhibits accelerated rejection mediated by memory T cells to induce long-lived heart allograft acceptance in mice. Immunol Lett 2011, 138:122-128.
90. Eggenhofer E., Renner P., Soeder Y., Popp F.C., Hoogduijn M.J., Geissler E.K., et al. Features of synergism between mesenchymal stem cells and immunosuppressive drugs in a murine heart transplantation model. Transpl Immunol 2011, [Epub ahead of print].